First patient set to receive controversial Biogen Alzheimer’s drug

June 16th, 20210 On Wednesday, a U.S. hospital  will give the first infusion of an expensive, controversial new Alzheimer’s drug from Biogen Inc. before Medicare had even said what it will pay for — and with some doctors upset by its approval last week. The first administration of the drug, Aduhelm, outside of a clinical trial is scheduled to take...